# EDGAR Filing Document

**Accession Number:** 0002030763
**File Stem:** 0001641172-25-025831
**Filing Date:** 2025-8
**Character Count:** 4305
**Document Hash:** cece0fd1f80929db4be3c1a768eab336
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-025831.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001641172-25-025831

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250828

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Wellgistics Health, Inc.
- **CENTRAL INDEX KEY:** 0002030763
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 933264234
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 3000 BAYPORT DRIVE SUITE 950
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33607
- **BUSINESS PHONE:** 1-843-302-1785

**MAIL ADDRESS:**
- **STREET 1:** 3000 BAYPORT DRIVE SUITE 950
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33607

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Danam Health, Inc
- **DATE OF NAME CHANGE:** 20240717

---

| | |
|:---|:---|
| ![](formcorresp_001.jpg) | **Dykema Gossett PLLC**<br>111 E. Kilbourn Ave.<br> Suite 1050<br> Milwaukee, WI 53202<br> www.dykema.com<br> Tel: 414-488-7300<br>|
|  | **Kate Bechen**<br>Direct Dial: (414) 488-7333<br> Email: KBechen@dykema.com |

---

August 28, 2025

U.S. Securities and Exchange Commission

Division of Corporate Finance

Office of Trade & Services

100 F Street, N.E.

Washington, D.C. 20549

Attention: Nicholas Nalbantian

---

| | |
|:---|:---|
| **Re:** | **Wellgistics Health, Inc.**<br> **Registration Statement on Form S-1**<br> **Filed July 24, 2025**<br> **File No. 333-288932** |

---

Dear Mr. Nalbantian:

This response letter (this "**Response**") is submitted on behalf of Wellgistics Health, Inc. (the "**Company**") in response to the comments that the Company received from the staff of the Division of Corporation Finance (the "**Staff**") of the U.S. Securities and Exchange Commission (the "**SEC**") in a letter addressed to Mr. Norton, dated August 8, 2025 (the "**Comment Letter**"), with respect to the Company's Registration Statement on Form S-1 (the "**Registration Statement**"), filed with the SEC on July 24, 2025. The Company is concurrently submitting the first amendment to the Registration Statement ("**Amendment No. 1**").

For reference purposes, each of the Staff's numbered comments from the Comment Letter is set forth in bold text below, followed by the Company's response to each comment. The responses below are based on information provided to Dykema Gossett PLLC by the Company.

<u>Registration Statement on Form S-1</u>

<u>Use of Proceeds, page 11</u>

**1.** **We note the disclosure surrounding your planned XRP Treasury Strategy and its execution in "the near future." If you intend on using the proceeds of this offering to purchase XRP to further your XRP Treasury Strategy, please disclose as much in this section. Refer to Instruction 5 to Item 504 of Regulation S-K.** 

*<u>Response</u>:* In response the Staff's comment, the Company respectfully advises the Staff that the Company does not intend on using the proceeds of this offering to purchase XRP.

California \| Illinois \| Michigan \| Minnesota \| Texas \| Washington, D.C. \| Wisconsin

U.S. Securities and Exchange Commission

Division of Corporate Finance

August 28, 2025

**2.** **We note the disclosure surrounding your planned acquisition of Peek Healthcare Technologies, Inc. If you intend on using the proceeds of this offering to finance the acquisition of Peek Healthcare Technologies, Inc., please disclose as much in this section. Refer to Instruction 6 to Item 504 of Regulation S-K.** 

*<u>Response</u>:* In response the Staff's comment, the Company respectfully advises the Staff that the Company does not intend on using the proceeds of this offering to finance the Company's acquisition of Peek Healthcare Technologies, Inc..

**\* \* \***

Thank you for your review and consideration of the matters set forth in this Response and in Amendment No. 1. If you have any questions, please contact the undersigned at (414) 488-7333 or KBechen@dykema.com.

---

| |
|:---|
| Sincerely, |
| **Dykema Gossett PLLC** |
| */s/ Kate Bechen* |
| Kate Bechen, Esq. |

---

cc: Brian Norton <br> Chief Executive Officer <br> Wellgistics Health, Inc.